Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.

Journal article

Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

Journal article

EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Journal article

Mayne K. et al, (2023), Journal of the American Society of Nephrology

SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA

Journal article

Mark PB. et al, (2023), Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 38, 2444 - 2455

Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.

Journal article

Writing Group for the CKD Prognosis Consortium None. et al, (2023), JAMA, 330, 1266 - 1277

Empagliflozin in Patients with Chronic Kidney Disease. Reply.

Journal article

Herrington WG. et al, (2023), N Engl J Med, 388, 2301 - 2302

Diabetes and infectious disease mortality in Mexico City.

Journal article

Bragg F. et al, (2023), BMJ Open Diabetes Res Care, 11

Empagliflozin in Patients with Chronic Kidney Disease.

Journal article

The EMPA-KIDNEY Collaborative Group None. et al, (2023), N Engl J Med, 388, 117 - 127

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.

Journal article

Donovan K. et al, (2023), Clin J Am Soc Nephrol, 18, 17 - 27

Load More